{
    "clinical_study": {
        "@rank": "73758", 
        "arm_group": [
            {
                "arm_group_label": "MT-4666 Low Dose", 
                "arm_group_type": "Experimental", 
                "description": "low dose"
            }, 
            {
                "arm_group_label": "MT-4666 High Dose", 
                "arm_group_type": "Experimental", 
                "description": "high dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the safety and efficacy as assessed by the\n      Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of\n      MT-4666 or placebo administered daily for 24 weeks to subjects with mild to moderate\n      Alzheimer's disease."
        }, 
        "brief_title": "Safety and Efficacy of MT-4666", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Probable Alzheimer's disease consistent with National Institute of Neurological and\n             Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related\n             Disorders Association (ADRDA) criteria\n\n          -  MMSE score of 10 to 24 inclusive at screening and at Day 1, and CDR-SB score of \u2265 2\n             at screening\n\n          -  Modified Hachinski Ischemic Score (mHIS) \u2264 4 at screening\n\n          -  Caregiver available; caregiver sees subject at least four days (at least 12 hours)\n             each week\n\n          -  Subject living at home; if living at senior residential setting, or an institutional\n             setting, subject with caregiver indicated above is available\n\n        Exclusion Criteria:\n\n          -  Inability to perform cognitive tests (ADAS-cog-13 and MMSE) at screening and at Day 1\n\n          -  Diagnosis of any other disease which may cause dementia\n\n          -  MRI or CT scan within 6 months before screening, with findings inconsistent with the\n             diagnosis of Probable AD\n\n          -  Diagnosis of major depressive disorder as defined by Diagnostic and Statistical\n             Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) within last\n             five years\n\n          -  History of or current diagnosis of any psychosis\n\n          -  History of myocardial infarction or unstable angina within six months before\n             screening\n\n          -  History of cerebrovascular disorder within 18 months before screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764243", 
            "org_study_id": "P211-03"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MT-4666 Low Dose", 
                    "MT-4666 High Dose"
                ], 
                "description": "low dose, high dose", 
                "intervention_name": "MT-4666", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Central Nervous System Agents", 
                "Nicotinic Agonists"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Alzheimer's Disease", 
            "Nicotinic Acetylcholine Receptor Agonist", 
            "Cognitive function", 
            "Dementia", 
            "Central Nervous System Agents"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kanto", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.", 
        "overall_contact": {
            "email": "cti-inq-ml@ml.mt-pharma.co.jp", 
            "last_name": "Clinical Trials Information Desk"
        }, 
        "overall_official": [
            {
                "affiliation": "Kagawa University School of Medicine", 
                "last_name": "Yu Nakamura, M.D., Ph.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Tokyo Dementia Care Research and Training Center", 
                "last_name": "Akira Homma, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Sapporo Medical University", 
                "last_name": "Shun Shimohama, M.D., D. Med. SC", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in ADAS-cog-13", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764243"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change from baseline in Alzheimers Disease Assessment Scale-cognitive subscale 11-item (ADAS-cog-11)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change from baseline in Mini-Mental State Examination (MMSE)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change from baseline in Neuropsychiatric Inventory (NPI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change from baseline in Modified Crichton Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}